Parecoxib perishes?
Executive Summary
FDA finds the injectable COX-2 inhibitor parecoxib "not approvable," Pfizer says Sept. 20. The company plans to meet with FDA "as soon as possible" to discuss the future of the application and says it "disagrees with the conclusions" made by FDA in the letter. FDA previously found parecoxib not approvable in 2001; that review raised questions about the product's efficacy and safety (1"The Pink Sheet" Feb. 14, 2005, p. 11)...
You may also be interested in...
FDA Discloses Safety Reviews Of COX-2s Arcoxia, Prexige and Parecoxib
Merck's Arcoxia is linked to an increase in cardiovascular adverse events across multiple analyses, FDA reviewers state in briefing documents for the upcoming COX-2 inhibitor safety review
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.